EHA 2019: Inhibitions of complement C3 in patients with autoimmune haemolytic anemia controls haemolysis and increases haemoglobine levels

Bruno Fattizzo | EHA 2019 | Juni 17, 2019

Föreläsare: Bruno Fattizzo

Autoimmune haemolytic anaemia is characterized by haemolysis mediated by autoantibodies directed against red blood cells. Complement C3b deposition on red blood cells plays a central role in autoimmune haemolytic anaemia. 

In this MEDtalk Bruno Fattizzo present new data that shows APL-2, a cyclic peptide, has potential as a novel therapeutic for autoimmune haemolytic anaemia.